Wedbush analyst Yun Zhong reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report) today and set a price target of $9.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yun Zhong has given his Buy rating due to a combination of factors that reflect both challenges and opportunities for Voyager Therapeutics. Despite the removal of the SOD1-ALS program from valuation, which led to a decrease in the price target from $11 to $9, Yun Zhong remains optimistic about the company’s prospects. This optimism is largely driven by promising developments in their tau-silencing program, VY1706, designed for Alzheimer’s disease. The non-human primate (NHP) studies have shown robust target mRNA knockdown and no dose-limiting toxicity, supporting the safety and efficacy of the AAV capsid used in the program.
Furthermore, Voyager’s financial health and strategic plans bolster this positive outlook. The company has a strong cash position, extending its runway into mid-2027. Additionally, other investigational new drug (IND) submissions for programs targeting Parkinson’s disease and Friedreich’s Ataxia are on schedule for 2025, with VY1706 set for 2026. These factors, combined with the potential for significant advancements in Alzheimer’s treatment, underpin Yun Zhong’s Buy recommendation, suggesting confidence in Voyager Therapeutics’ long-term growth potential.
In another report released on January 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.